Pharmacokinetics
Following a single‐dose oral administration of 2, 4, 6, or 8 mg in patients with ABC, HS‐10352 was rapidly absorbed. The median times to peak (Concentration–time curves in the 2, 4, 6, and 8 mg QD groups after single‐dose administration in Cycle 0 (A) and multiple‐dose administration in Cycle 2 (B).After multiple‐dose administrations, HS‐10352 reached the steady state by Day 8, with mean steady‐state maximum blood concentration (